3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Thoracic
2
Breast
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Classical hematology
1
Conditions
Melanoma
5
Uterine Cervical Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Noonan Syndrome 6
1
Glioblastoma
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
pembrolizumab
16
Cyclophosphamide
8
Nivolumab
7
Gemcitabine
6
Paclitaxel
5
Drug Therapy
5
Docetaxel
5
fludarabine
4
aldesleukin
4
Oxaliplatin
4
Fluorouracil
4
Carboplatin
4
ulixertinib
3
spartalizumab
3
Trastuzumab
3
Radiotherapy
3
Leucovorin
3
Capecitabine
3
trametinib
2
tovorafenib
2
pertuzumab
2
pegilodecakin
2
pazopanib
2
palbociclib
2
osimertinib
2
enzalutamide
2
cemiplimab
2
atezolizumab
2
Taxes
2
Specimen Handling
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
regorafenib
×
Dermatologic
×
Clear all
NCT02307500
2022-09-10
RESOUND
Istituto Clinico Humanitas
Phase 2
Completed
82 enrolled